TransCode Therapeutics (NASDAQ:RNAZ) Announces Quarterly Earnings Results

TransCode Therapeutics (NASDAQ:RNAZ) issued its quarterly earnings results on Wednesday. The company reported $999.00 earnings per share for the quarter, Zacks reports.

TransCode Therapeutics Stock Up 0.1%

Shares of RNAZ stock traded up $0.01 on Wednesday, reaching $8.91. 5,530 shares of the stock were exchanged, compared to its average volume of 216,472. The stock has a market cap of $8.20 million, a P/E ratio of -0.33 and a beta of 1.49. The firm has a 50 day moving average of $9.32 and a two-hundred day moving average of $9.68. TransCode Therapeutics has a 1-year low of $6.08 and a 1-year high of $22.03.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $280.00.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.